Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:32:18 CEST | news aktuell GmbH | Press Release
Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients. Joining the CNATM provides Grünenthal with a valuable platform to strengthen its oligonucleotide drug discovery capabilities and connect its growing internal expertise with one of Germany’s leading academic and biotech innovation ecosystems. Over the last few years, Grünenthal has built strategic in-house capabilities to advance oligonucleotide modalities, including antisense oligonucleotides (ASOs) and small interfering RNA (siRNA), as potential therapeutic approaches for pain and related neurological indications. One of Grünenthal’s key objectives for the collaboration